Prescription Transdermal Patch Abuse and Accidental Pediatric Exposure Remains a Serious Problem in the United States - Surveillance Data to Be Presented at 2024 American Academy of Pain Medicine Annual Meeting - Seite 2

The study conducted by RMPDS quantified US trends in intentional abuse and misuse and accidental pediatric exposures to fentanyl, buprenorphine, and methylphenidate transdermal patches as well as a comparative evaluation of oral buprenorphine dose forms used in opioid use disorder. The study findings indicate that transdermal patch abuse and accidental pediatric exposures to patches continue to be a serious problem resulting in major medical outcomes and death, suggesting an unmet need for safer abuse deterrent versions of these patches. Full study results will be presented at the AAPM Conference in the abstract poster session.

Nutriband's lead product is AVERSA Fentanyl which combines Nutriband's proprietary AVERSA abuse-deterrent transdermal technology with an already FDA-approved transdermal fentanyl patch and has the potential to become the world's first opioid patch with abuse deterrent properties.AVERSA Fentanyl is estimated to have the potential to reach peak annual US sales of $80M - $200M.²

¹ https://www.fda.gov/consumers/consumer-updates/accidental-exposures-fe ...

² Health Advances Aversa Fentanyl market analysis report 2022

About AVERSA Abuse Deterrent Transdermal Technology

Nutriband's AVERSA abuse-deterrent transdermal technology can be utilized to incorporate aversive agents into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential. The AVERSA abuse-deterrent technology has the potential to improve the safety profile of transdermal drugs susceptible to abuse, such as fentanyl, while making sure that these drugs remain accessible to those patients who really need them. The technology is covered by a broad intellectual property portfolio with patents granted in the United States, Europe, Japan, Korea, Russia, Canada, Mexico, and Australia.

About Nutriband Inc.

We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse deterrent fentanyl patch incorporating our AVERSA abuse-deterrent technology. AVERSA technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.

The Company's website is www.nutriband.com. Any material contained in or derived from the Company's websites or any other website is not part of this press release.